BRAF and neoplasm: BRAF V600K variants were reported to be more aggressive than BRAF V600E ones since they have a shorter disease-free interval from diagnosis of primary melanoma to the occurrence of first distant metastasis, as well as inferior tumor regression and shorter PFS when treated with BRAF and MEK inhibitors [106].